Stem definition | Drug id | CAS RN |
---|---|---|
antihypertensive substances, prazosin derivatives | 115 | 81403-80-7 |
Dose | Unit | Route |
---|---|---|
7.50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.34 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 55 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.14 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 12, 2003 | FDA | COVIS PHARMA SARL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Apraxia | 66.35 | 41.63 | 13 | 947 | 1532 | 50602632 |
Dementia | 60.09 | 41.63 | 19 | 941 | 15978 | 50588186 |
Disorientation | 52.14 | 41.63 | 21 | 939 | 35463 | 50568701 |
Perseveration | 51.08 | 41.63 | 8 | 952 | 255 | 50603909 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug dispensed to wrong patient | 142.99 | 13.51 | 33 | 17208 | 242 | 29557044 |
Acute kidney injury | 119.61 | 13.51 | 382 | 16859 | 264885 | 29292401 |
Orthostatic hypotension | 90.46 | 13.51 | 87 | 17154 | 22542 | 29534744 |
Syncope | 81.11 | 13.51 | 159 | 17082 | 81212 | 29476074 |
Fall | 76.69 | 13.51 | 252 | 16989 | 176926 | 29380360 |
Antimicrobial susceptibility test resistant | 66.70 | 13.51 | 18 | 17223 | 264 | 29557022 |
Confusional state | 66.51 | 13.51 | 194 | 17047 | 127683 | 29429603 |
Wrong patient received product | 64.83 | 13.51 | 30 | 17211 | 2252 | 29555034 |
Cholestasis | 64.72 | 13.51 | 74 | 17167 | 23388 | 29533898 |
Hepatocellular injury | 63.73 | 13.51 | 70 | 17171 | 21173 | 29536113 |
Agranulocytosis | 57.53 | 13.51 | 65 | 17176 | 20275 | 29537011 |
Therapeutic response delayed | 54.11 | 13.51 | 17 | 17224 | 435 | 29556851 |
Toxicity to various agents | 50.65 | 13.51 | 19 | 17222 | 173642 | 29383644 |
Thrombocytopenia | 49.73 | 13.51 | 182 | 17059 | 134641 | 29422645 |
Hypotension | 47.98 | 13.51 | 232 | 17009 | 194122 | 29363164 |
Urinary retention | 46.89 | 13.51 | 74 | 17167 | 31824 | 29525462 |
Eosinophilia | 43.59 | 13.51 | 59 | 17182 | 22102 | 29535184 |
Coma | 40.35 | 13.51 | 78 | 17163 | 39372 | 29517914 |
Staring | 38.77 | 13.51 | 18 | 17223 | 1361 | 29555925 |
Pemphigoid | 37.79 | 13.51 | 33 | 17208 | 7548 | 29549738 |
Drug interaction | 37.32 | 13.51 | 219 | 17022 | 197166 | 29360120 |
Allergy to animal | 36.29 | 13.51 | 11 | 17230 | 249 | 29557037 |
Disorganised speech | 36.24 | 13.51 | 14 | 17227 | 669 | 29556617 |
Product storage error | 33.94 | 13.51 | 29 | 17212 | 6441 | 29550845 |
Cell death | 32.07 | 13.51 | 18 | 17223 | 2026 | 29555260 |
Completed suicide | 31.55 | 13.51 | 7 | 17234 | 90239 | 29467047 |
Daydreaming | 29.63 | 13.51 | 11 | 17230 | 471 | 29556815 |
Brain stem haematoma | 29.48 | 13.51 | 8 | 17233 | 120 | 29557166 |
Wrong product administered | 29.43 | 13.51 | 23 | 17218 | 4508 | 29552778 |
Dermatitis exfoliative generalised | 28.57 | 13.51 | 19 | 17222 | 2897 | 29554389 |
Nasal discomfort | 28.52 | 13.51 | 14 | 17227 | 1198 | 29556088 |
Product dispensing error | 27.61 | 13.51 | 24 | 17217 | 5456 | 29551830 |
Petit mal epilepsy | 27.31 | 13.51 | 18 | 17223 | 2704 | 29554582 |
Minimum inhibitory concentration | 25.99 | 13.51 | 6 | 17235 | 44 | 29557242 |
Blood thyroid stimulating hormone decreased | 25.97 | 13.51 | 15 | 17226 | 1783 | 29555503 |
Parkinsonism | 25.39 | 13.51 | 26 | 17215 | 7252 | 29550034 |
Product administration error | 25.00 | 13.51 | 36 | 17205 | 14274 | 29543012 |
Post procedural haemorrhage | 24.77 | 13.51 | 26 | 17215 | 7465 | 29549821 |
Neutropenia | 24.75 | 13.51 | 146 | 17095 | 131565 | 29425721 |
Vertigo | 24.55 | 13.51 | 45 | 17196 | 21816 | 29535470 |
Subileus | 24.20 | 13.51 | 17 | 17224 | 2833 | 29554453 |
Toxic skin eruption | 23.94 | 13.51 | 29 | 17212 | 9728 | 29547558 |
Altered state of consciousness | 23.68 | 13.51 | 42 | 17199 | 19847 | 29537439 |
Soft tissue mass | 23.32 | 13.51 | 10 | 17231 | 626 | 29556660 |
Diffuse large B-cell lymphoma recurrent | 23.25 | 13.51 | 16 | 17225 | 2581 | 29554705 |
Melaena | 23.02 | 13.51 | 54 | 17187 | 31122 | 29526164 |
Stool analysis abnormal | 22.98 | 13.51 | 5 | 17236 | 27 | 29557259 |
Hyperlipasaemia | 22.39 | 13.51 | 9 | 17232 | 478 | 29556808 |
Illusion | 22.37 | 13.51 | 10 | 17231 | 692 | 29556594 |
Hypokalaemia | 22.14 | 13.51 | 72 | 17169 | 50131 | 29507155 |
Purpura | 21.94 | 13.51 | 27 | 17214 | 9205 | 29548081 |
Campylobacter gastroenteritis | 21.79 | 13.51 | 10 | 17231 | 736 | 29556550 |
Febrile neutropenia | 21.79 | 13.51 | 20 | 17221 | 112220 | 29445066 |
Incontinence | 21.33 | 13.51 | 20 | 17221 | 5012 | 29552274 |
Dysuria | 21.28 | 13.51 | 43 | 17198 | 22397 | 29534889 |
Dissociation | 20.64 | 13.51 | 11 | 17230 | 1118 | 29556168 |
Hanging | 20.49 | 13.51 | 6 | 17235 | 120 | 29557166 |
Capillary fragility | 20.46 | 13.51 | 5 | 17236 | 48 | 29557238 |
Febrile bone marrow aplasia | 19.94 | 13.51 | 23 | 17218 | 7328 | 29549958 |
Bradycardia | 19.60 | 13.51 | 83 | 17158 | 65546 | 29491740 |
Normocytic anaemia | 19.57 | 13.51 | 13 | 17228 | 1979 | 29555307 |
Hepatitis cholestatic | 19.43 | 13.51 | 22 | 17219 | 6871 | 29550415 |
Steroid diabetes | 18.92 | 13.51 | 12 | 17229 | 1689 | 29555597 |
Dizziness | 18.91 | 13.51 | 181 | 17060 | 189503 | 29367783 |
Haemoglobinaemia | 18.86 | 13.51 | 6 | 17235 | 160 | 29557126 |
Prostatomegaly | 18.76 | 13.51 | 18 | 17223 | 4643 | 29552643 |
Hallucination | 18.70 | 13.51 | 63 | 17178 | 44649 | 29512637 |
Vitamin B12 decreased | 18.53 | 13.51 | 10 | 17231 | 1042 | 29556244 |
Hallucination, visual | 18.25 | 13.51 | 32 | 17209 | 14983 | 29542303 |
Pelvic fracture | 18.23 | 13.51 | 13 | 17228 | 2218 | 29555068 |
Hypernatraemia | 18.20 | 13.51 | 22 | 17219 | 7364 | 29549922 |
Hypovolaemic shock | 18.18 | 13.51 | 20 | 17221 | 6052 | 29551234 |
On and off phenomenon | 17.54 | 13.51 | 12 | 17229 | 1916 | 29555370 |
Growth hormone deficiency | 16.94 | 13.51 | 6 | 17235 | 224 | 29557062 |
Cardiac failure congestive | 16.91 | 13.51 | 12 | 17229 | 76569 | 29480717 |
Anaemia | 16.81 | 13.51 | 185 | 17056 | 200766 | 29356520 |
Tonic clonic movements | 16.78 | 13.51 | 9 | 17232 | 926 | 29556360 |
Hepatitis | 16.44 | 13.51 | 37 | 17204 | 20746 | 29536540 |
Angina pectoris | 16.13 | 13.51 | 44 | 17197 | 27806 | 29529480 |
Hyponatraemia | 16.08 | 13.51 | 80 | 17161 | 67553 | 29489733 |
Hyperkeratosis | 15.83 | 13.51 | 14 | 17227 | 3255 | 29554031 |
Hyperkalaemia | 15.59 | 13.51 | 74 | 17167 | 61318 | 29495968 |
Expired product administered | 15.57 | 13.51 | 13 | 17228 | 2798 | 29554488 |
Presyncope | 15.45 | 13.51 | 31 | 17210 | 16058 | 29541228 |
Death | 15.27 | 13.51 | 127 | 17114 | 341957 | 29215329 |
Amaurosis fugax | 15.19 | 13.51 | 7 | 17234 | 520 | 29556766 |
Cystitis interstitial | 15.00 | 13.51 | 5 | 17236 | 155 | 29557131 |
Blood pressure decreased | 14.74 | 13.51 | 59 | 17182 | 45418 | 29511868 |
Paramnesia | 14.73 | 13.51 | 3 | 17238 | 11 | 29557275 |
Behaviour disorder | 14.62 | 13.51 | 14 | 17227 | 3602 | 29553684 |
Ketonuria | 14.55 | 13.51 | 7 | 17234 | 573 | 29556713 |
Hyperhidrosis | 14.40 | 13.51 | 75 | 17166 | 64465 | 29492821 |
Dyspnoea at rest | 14.06 | 13.51 | 13 | 17228 | 3201 | 29554085 |
Eczema | 13.71 | 13.51 | 27 | 17214 | 13799 | 29543487 |
Pancreatitis acute | 13.60 | 13.51 | 38 | 17203 | 24347 | 29532939 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 194.94 | 13.88 | 371 | 15261 | 448869 | 64034231 |
Confusional state | 91.70 | 13.88 | 198 | 15434 | 260946 | 64222154 |
Drug interaction | 87.94 | 13.88 | 238 | 15394 | 361845 | 64121255 |
Cholestasis | 84.73 | 13.88 | 77 | 15555 | 44795 | 64438305 |
Orthostatic hypotension | 83.97 | 13.88 | 78 | 15554 | 46660 | 64436440 |
Thrombocytopenia | 78.87 | 13.88 | 170 | 15462 | 223631 | 64259469 |
Drug dispensed to wrong patient | 77.20 | 13.88 | 18 | 15614 | 359 | 64482741 |
Antimicrobial susceptibility test resistant | 76.80 | 13.88 | 17 | 15615 | 266 | 64482834 |
Syncope | 76.47 | 13.88 | 137 | 15495 | 157498 | 64325602 |
Agranulocytosis | 74.93 | 13.88 | 67 | 15565 | 38162 | 64444938 |
Hepatocellular injury | 70.85 | 13.88 | 70 | 15562 | 45165 | 64437935 |
Fall | 69.32 | 13.88 | 240 | 15392 | 416586 | 64066514 |
Hypotension | 62.12 | 13.88 | 218 | 15414 | 380756 | 64102344 |
Urinary retention | 57.24 | 13.88 | 65 | 15567 | 49136 | 64433964 |
Eosinophilia | 56.09 | 13.88 | 57 | 15575 | 38019 | 64445081 |
Coma | 55.66 | 13.88 | 86 | 15546 | 87529 | 64395571 |
Therapeutic response delayed | 53.27 | 13.88 | 16 | 15616 | 866 | 64482234 |
Neutropenia | 51.64 | 13.88 | 151 | 15481 | 239473 | 64243627 |
Wrong patient received product | 48.96 | 13.88 | 22 | 15610 | 3740 | 64479360 |
Pemphigoid | 47.73 | 13.88 | 33 | 15599 | 12953 | 64470147 |
Hallucination, visual | 45.30 | 13.88 | 44 | 15588 | 27790 | 64455310 |
Staring | 44.30 | 13.88 | 18 | 15614 | 2392 | 64480708 |
Wrong product administered | 39.12 | 13.88 | 24 | 15608 | 7696 | 64475404 |
Disorganised speech | 36.18 | 13.88 | 14 | 15618 | 1636 | 64481464 |
Hyperkalaemia | 35.74 | 13.88 | 77 | 15555 | 101052 | 64382048 |
Cell death | 35.34 | 13.88 | 18 | 15614 | 4036 | 64479064 |
Completed suicide | 35.24 | 13.88 | 6 | 15626 | 224408 | 64258692 |
Pain | 35.03 | 13.88 | 50 | 15582 | 553461 | 63929639 |
Daydreaming | 33.49 | 13.88 | 11 | 15621 | 799 | 64482301 |
Altered state of consciousness | 32.59 | 13.88 | 43 | 15589 | 37859 | 64445241 |
Minimum inhibitory concentration | 31.74 | 13.88 | 6 | 15626 | 40 | 64483060 |
Petit mal epilepsy | 31.68 | 13.88 | 18 | 15614 | 5014 | 64478086 |
Dermatitis exfoliative generalised | 31.54 | 13.88 | 19 | 15613 | 5897 | 64477203 |
Brain stem haematoma | 31.24 | 13.88 | 7 | 15625 | 116 | 64482984 |
Allergy to animal | 30.99 | 13.88 | 11 | 15621 | 1010 | 64482090 |
Toxic skin eruption | 30.47 | 13.88 | 30 | 15602 | 19254 | 64463846 |
Bradycardia | 29.86 | 13.88 | 79 | 15553 | 118140 | 64364960 |
Parkinsonism | 29.76 | 13.88 | 26 | 15606 | 14347 | 64468753 |
Melaena | 29.12 | 13.88 | 49 | 15583 | 53499 | 64429601 |
Disorientation | 28.93 | 13.88 | 50 | 15582 | 55778 | 64427322 |
Haematuria | 28.55 | 13.88 | 52 | 15580 | 60419 | 64422681 |
Soft tissue mass | 28.38 | 13.88 | 10 | 15622 | 899 | 64482201 |
Prostatomegaly | 28.29 | 13.88 | 14 | 15618 | 2953 | 64480147 |
Toxicity to various agents | 28.12 | 13.88 | 28 | 15604 | 363485 | 64119615 |
Perseveration | 27.77 | 13.88 | 8 | 15624 | 374 | 64482726 |
Apraxia | 27.49 | 13.88 | 13 | 15619 | 2482 | 64480618 |
Drug intolerance | 27.45 | 13.88 | 6 | 15626 | 187986 | 64295114 |
Hepatitis cholestatic | 27.23 | 13.88 | 23 | 15609 | 12132 | 64470968 |
Alopecia | 26.97 | 13.88 | 4 | 15628 | 165686 | 64317414 |
Febrile bone marrow aplasia | 26.67 | 13.88 | 22 | 15610 | 11233 | 64471867 |
Campylobacter gastroenteritis | 26.38 | 13.88 | 10 | 15622 | 1106 | 64481994 |
Status epilepticus | 25.83 | 13.88 | 29 | 15603 | 21634 | 64461466 |
Purpura | 25.72 | 13.88 | 26 | 15606 | 17220 | 64465880 |
Headache | 25.23 | 13.88 | 57 | 15575 | 529410 | 63953690 |
Rheumatoid arthritis | 24.48 | 13.88 | 5 | 15627 | 164289 | 64318811 |
Prostate cancer | 24.46 | 13.88 | 27 | 15605 | 19768 | 64463332 |
On and off phenomenon | 24.36 | 13.88 | 12 | 15620 | 2507 | 64480593 |
Product dispensing error | 24.29 | 13.88 | 21 | 15611 | 11429 | 64471671 |
Hypovolaemic shock | 24.18 | 13.88 | 20 | 15612 | 10246 | 64472854 |
Hyponatraemia | 24.17 | 13.88 | 85 | 15547 | 148254 | 64334846 |
Hallucination | 24.10 | 13.88 | 54 | 15578 | 72734 | 64410366 |
Subileus | 24.02 | 13.88 | 15 | 15617 | 4962 | 64478138 |
Tonic clonic movements | 23.89 | 13.88 | 11 | 15621 | 1978 | 64481122 |
Steroid diabetes | 23.71 | 13.88 | 12 | 15620 | 2654 | 64480446 |
Hyperlipasaemia | 23.69 | 13.88 | 9 | 15623 | 1001 | 64482099 |
Blood thyroid stimulating hormone decreased | 23.34 | 13.88 | 15 | 15617 | 5215 | 64477885 |
Nasal discomfort | 23.33 | 13.88 | 14 | 15618 | 4314 | 64478786 |
Illusion | 23.07 | 13.88 | 10 | 15622 | 1560 | 64481540 |
Behaviour disorder | 22.94 | 13.88 | 14 | 15618 | 4448 | 64478652 |
Bicytopenia | 22.92 | 13.88 | 13 | 15619 | 3609 | 64479491 |
Hepatitis | 22.54 | 13.88 | 40 | 15592 | 45542 | 64437558 |
Infusion related reaction | 22.54 | 13.88 | 6 | 15626 | 164461 | 64318639 |
Dehydration | 21.75 | 13.88 | 107 | 15525 | 216656 | 64266444 |
Pancreatitis acute | 21.70 | 13.88 | 38 | 15594 | 42817 | 64440283 |
Haemoglobinaemia | 21.38 | 13.88 | 6 | 15626 | 255 | 64482845 |
Hanging | 21.24 | 13.88 | 5 | 15627 | 104 | 64482996 |
Hypokalaemia | 20.85 | 13.88 | 71 | 15561 | 121832 | 64361268 |
Product administration error | 20.21 | 13.88 | 29 | 15603 | 27614 | 64455486 |
Swelling | 19.87 | 13.88 | 7 | 15625 | 160211 | 64322889 |
Pneumonia aspiration | 19.65 | 13.88 | 44 | 15588 | 59227 | 64423873 |
Growth hormone deficiency | 19.62 | 13.88 | 6 | 15626 | 345 | 64482755 |
Dissociation | 19.58 | 13.88 | 11 | 15621 | 3000 | 64480100 |
Incontinence | 19.47 | 13.88 | 19 | 15613 | 12062 | 64471038 |
Normocytic anaemia | 18.64 | 13.88 | 11 | 15621 | 3288 | 64479812 |
Treatment failure | 18.60 | 13.88 | 3 | 15629 | 116813 | 64366287 |
Dysuria | 18.39 | 13.88 | 35 | 15597 | 42022 | 64441078 |
Psychomotor hyperactivity | 18.36 | 13.88 | 20 | 15612 | 14431 | 64468669 |
Amaurosis fugax | 18.24 | 13.88 | 7 | 15625 | 800 | 64482300 |
Pulmonary interstitial emphysema syndrome | 17.99 | 13.88 | 6 | 15626 | 457 | 64482643 |
Capillary fragility | 17.97 | 13.88 | 5 | 15627 | 206 | 64482894 |
Hyperkeratosis | 17.82 | 13.88 | 14 | 15618 | 6667 | 64476433 |
Nausea | 17.62 | 13.88 | 115 | 15517 | 785685 | 63697415 |
Vertigo | 17.57 | 13.88 | 42 | 15590 | 58969 | 64424131 |
Blood pressure decreased | 17.27 | 13.88 | 53 | 15579 | 86146 | 64396954 |
Subdural haematoma | 17.05 | 13.88 | 27 | 15605 | 28027 | 64455073 |
Dementia | 16.99 | 13.88 | 23 | 15609 | 20743 | 64462357 |
Expired product administered | 16.96 | 13.88 | 13 | 15619 | 5974 | 64477126 |
Gynaecomastia | 16.90 | 13.88 | 13 | 15619 | 6003 | 64477097 |
Anaemia | 16.58 | 13.88 | 152 | 15480 | 378528 | 64104572 |
Amyotrophy | 16.55 | 13.88 | 6 | 15626 | 585 | 64482515 |
Disturbance in attention | 16.52 | 13.88 | 33 | 15599 | 41041 | 64442059 |
Drug hypersensitivity | 16.51 | 13.88 | 20 | 15612 | 237795 | 64245305 |
Gout | 16.44 | 13.88 | 23 | 15609 | 21390 | 64461710 |
Presyncope | 16.34 | 13.88 | 30 | 15602 | 35059 | 64448041 |
Dyspnoea at rest | 16.32 | 13.88 | 13 | 15619 | 6316 | 64476784 |
Intraventricular haemorrhage | 16.32 | 13.88 | 11 | 15621 | 4142 | 64478958 |
Therapeutic product effect decreased | 16.20 | 13.88 | 4 | 15628 | 115347 | 64367753 |
Product storage error | 16.17 | 13.88 | 18 | 15614 | 13300 | 64469800 |
Lichenoid keratosis | 15.97 | 13.88 | 10 | 15622 | 3324 | 64479776 |
Cerebral haemorrhage | 15.90 | 13.88 | 37 | 15595 | 51053 | 64432047 |
Hyperhidrosis | 15.75 | 13.88 | 66 | 15566 | 124854 | 64358246 |
Oversensing | 15.74 | 13.88 | 3 | 15629 | 21 | 64483079 |
Cardiovascular insufficiency | 15.49 | 13.88 | 9 | 15623 | 2615 | 64480485 |
Pallor | 15.41 | 13.88 | 31 | 15601 | 38750 | 64444350 |
Abdominal discomfort | 15.31 | 13.88 | 13 | 15619 | 182309 | 64300791 |
Paramnesia | 15.18 | 13.88 | 3 | 15629 | 26 | 64483074 |
Inferior vena cava dilatation | 15.13 | 13.88 | 6 | 15626 | 748 | 64482352 |
Leukopenia | 14.78 | 13.88 | 56 | 15576 | 101186 | 64381914 |
Lactic acidosis | 14.45 | 13.88 | 40 | 15592 | 61370 | 64421730 |
Renal failure | 14.34 | 13.88 | 84 | 15548 | 181604 | 64301496 |
Atrioventricular block | 14.18 | 13.88 | 16 | 15616 | 11999 | 64471101 |
Atrioventricular block second degree | 14.02 | 13.88 | 12 | 15620 | 6442 | 64476658 |
Cardio-respiratory arrest | 14.01 | 13.88 | 54 | 15578 | 98339 | 64384761 |
Hypernatraemia | 13.99 | 13.88 | 16 | 15616 | 12173 | 64470927 |
None
Source | Code | Description |
---|---|---|
ATC | G04CA01 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists |
ATC | G04CA51 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists |
FDA MoA | N0000000099 | Adrenergic alpha-Antagonists |
FDA EPC | N0000175553 | alpha-Adrenergic Blocker |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D058668 | Adrenergic alpha-1 Receptor Antagonists |
MeSH PA | D000317 | Adrenergic alpha-Antagonists |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D064804 | Urological Agents |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:37890 | alpha-adrenergic receptor blockaders |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Benign prostatic hyperplasia | indication | 266569009 | |
Orthostatic hypotension | contraindication | 28651003 | |
Torsades de pointes | contraindication | 31722008 | |
Low blood pressure | contraindication | 45007003 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Cataract surgery | contraindication | 110473004 | |
Prolonged QT interval | contraindication | 111975006 | |
Angina pectoris | contraindication | 194828000 | |
Micturition syncope | contraindication | 234168001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Intraoperative floppy iris syndrome | contraindication | 418801006 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Progressive Angina Pectoris | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.09 | acidic |
pKa2 | 7.22 | Basic |
pKa3 | 0.97 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Alpha-1A adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.09 | CHEMBL | CHEMBL | |||
Alpha-1D adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.44 | CHEMBL | CHEMBL | |||
Alpha-1B adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.55 | CHEMBL | CHEMBL | |||
Acetylcholinesterase | Enzyme | IC50 | 7.75 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.83 | CHEMBL | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 8.46 | CHEMBL | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 7.64 | CHEMBL |
ID | Source |
---|---|
4021396 | VUID |
N0000148814 | NUI |
D01692 | KEGG_DRUG |
81403-68-1 | SECONDARY_CAS_RN |
17300 | RXNORM |
C0051150 | UMLSCUI |
CHEBI:51141 | CHEBI |
CHEMBL709 | ChEMBL_ID |
DB00346 | DRUGBANK_ID |
CHEMBL1723 | ChEMBL_ID |
C047638 | MESH_SUPPLEMENTAL_RECORD_UI |
2092 | PUBCHEM_CID |
7109 | IUPHAR_LIGAND_ID |
5357 | INN_ID |
90347YTW5F | UNII |
16517 | MMSL |
184661 | MMSL |
43057 | MMSL |
47077 | MMSL |
d04797 | MMSL |
005431 | NDDF |
005432 | NDDF |
4021396 | VANDF |
349912006 | SNOMEDCT_US |
395725004 | SNOMEDCT_US |
395954002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-5000 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
ALFUZOSIN HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-021 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 25 sections |
Uroxatral | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-279 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | NDA | 11 sections |
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-155 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 17 sections |
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-155 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 17 sections |
Alfuzosin Hydrochlorideextended release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-302 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-994 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 25 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-746 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin hydrochloride | Human Prescription Drug Label | 1 | 43353-945 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
Alfuzosin Hydrochloride | Human Prescription Drug Label | 1 | 47335-956 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Uroxatral | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5046 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | NDA | 28 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6329 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-738 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Alfuzosin Hydrochloride | Human Prescription Drug Label | 1 | 57237-114 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Uroxatral | Human Prescription Drug Label | 1 | 59212-200 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | NDA | 27 sections |
ALFUZOSIN HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-349 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 18 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2353 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2353 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2354 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2354 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-7907 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 17 sections |
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-7907 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 17 sections |
Alfuzosin hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-9155 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 17 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-9295 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-738 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
Alfuzosin Hydrochloride | Human Prescription Drug Label | 1 | 65862-249 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochlorideextended release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-844 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70934-306 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Alfuzosin Hydrochlorideextended release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70934-961 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Alfuzosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-1529 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |